Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885304 | 0.95 | RAB9A (0.39) | RETNPC1RAB9APRKCIKDM1A | |
| SCHEMBL5234662 | 0.90 | RET (0.35) | RETNPC1RAB9APRKCIKDM1A | |
| SCHEMBL8259326 | 0.89 | RET (0.40) | RETNPC1RAB9APRKCIKDM1A | |
| SCHEMBL4886035 | 0.85 | SCN5A (0.39) | RETNPC1RAB9AMAPTPOLB | |
| SCHEMBL8260824 | 0.83 | KMT2A (0.40) | RETNPC1RAB9AATR | |
| SCHEMBL4709549 | 0.82 | F10 (0.48) | — | |
| SCHEMBL4878211 | 0.81 | F10 (0.47) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5232007 | 0.80 | LMNA (0.39) | RETMAPTALDH1A1 | |
| SCHEMBL4882152 | 0.80 | KMT2A (0.38) | NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5236143 | 0.80 | RAB9A (0.43) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | BAYER HEALTHCARE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2006058630-A1 | CYCLIC IMINOCARBAMATES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214533-A1 | Cyclic Iminocarbamates And Their Use | F2, UQCRB, F12 | RET 2843/4885NPC1 1777/4885RAB9A 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.